REGENEREX PHARMA, INC.: 10-Q filed 2022-11-07

Name: REGENEREX PHARMA, INC.: 10-Q filed 2022-11-07
Creator: REGENEREX PHARMA, INC.

What REGENEREX PHARMA, INC. reported in its quarterly report filed 2022-11-07 (fiscal Q2 2022): 24 published measures, 71 facts as tagged in accession 0001472375-22-000113.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-07
Fiscal period: fiscal Q2 2022
Accession: 0001472375-22-000113 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	8,761	USD
At 2022-03-31	15,322	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	1,036,018	USD
At 2022-03-31	1,000,939	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	-1,027,257	USD
At 2022-06-30	-1,008,821	USD
At 2022-03-31	-985,617	USD
At 2021-09-30	-902,734	USD
At 2021-06-30	-868,978	USD
At 2021-03-31	-835,026	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2022-09-30	629	USD
At 2022-03-31	2,640	USD
At 2021-09-30	2,545	USD
At 2021-03-31	6,902	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-18,436	USD	92
2022-04-01 to 2022-09-30	-41,640	USD	183
2022-04-01 to 2022-06-30	-23,204	USD	91
2021-07-01 to 2021-09-30	-33,756	USD	92
2021-04-01 to 2021-09-30	-67,708	USD	183
2021-04-01 to 2021-06-30	-33,952	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-04-01 to 2022-09-30	-44,512	USD	183
2021-04-01 to 2021-09-30	-45,457	USD	183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-04-01 to 2022-09-30	42,501	USD	183
2021-04-01 to 2021-09-30	46,700	USD	183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-04-01 to 2021-09-30	-5,600	USD	183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-1,976,333	USD
At 2022-03-31	-1,934,693	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	277,112,660	shares	92
2022-04-01 to 2022-09-30	277,112,660	shares	183
2021-07-01 to 2021-09-30	127,112,660	shares	92
2021-04-01 to 2021-09-30	127,112,660	shares	183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-21,504	USD	92
2022-04-01 to 2022-09-30	-38,789	USD	183
2021-07-01 to 2021-09-30	-21,073	USD	92
2021-04-01 to 2021-09-30	-32,761	USD	183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	3,129	USD
At 2022-03-31	7,896	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	16,607	USD	92
2022-04-01 to 2022-09-30	32,125	USD	183
2021-07-01 to 2021-09-30	16,840	USD	92
2021-04-01 to 2021-09-30	29,582	USD	183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	780,354	USD
At 2022-03-31	660,453	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	66,191	USD
At 2022-03-31	63,027	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-09-30	5,632	USD
At 2022-03-31	7,426	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	21,504	USD	92
2022-04-01 to 2022-09-30	38,789	USD	183
2021-07-01 to 2021-09-30	21,073	USD	92
2021-04-01 to 2021-09-30	32,761	USD	183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	277,112,660	shares
At 2022-03-31	277,112,660	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	671,963	USD
At 2022-03-31	671,963	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-09-30	104,257	USD
At 2022-03-31	91,667	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	21,504	USD	92
2022-04-01 to 2022-09-30	38,789	USD	183
2021-07-01 to 2021-09-30	21,073	USD	92
2021-04-01 to 2021-09-30	32,761	USD	183

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-04-01 to 2022-09-30	1,794	USD	183
2021-04-01 to 2021-09-30	1,314	USD	183

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	723	USD	92
2022-04-01 to 2022-09-30	1,794	USD	183
2021-07-01 to 2021-09-30	816	USD	92
2021-04-01 to 2021-09-30	1,314	USD	183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	3,068	USD	92
2022-04-01 to 2022-09-30	-2,851	USD	183
2021-07-01 to 2021-09-30	-10,221	USD	92
2021-04-01 to 2021-09-30	-27,210	USD	183

Inspect the source

Entity: REGENEREX PHARMA, INC. / CIK 0001357878
Captured: 2026-09-21T17:18:44.819Z
SEC response SHA-256: 213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))